Drug Profile
SHP 623
Alternative Names: rC1-INH - Takeda; Recombinant-C1-esterase-Takeda; SHP623Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Shire
- Developer Takeda
- Class Complement C1 inactivator proteins; Recombinant proteins
- Mechanism of Action Complement C1 inhibitors; Complement system protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hereditary angioedema
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Hereditary-angioedema(In volunteers) in USA (IV)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Hereditary-angioedema(In volunteers) in USA (SC)
- 08 Jan 2019 Shire has been acquired and merged into Takeda